Searched over 200M research papers
7 papers analyzed
These studies suggest that lisinopril can increase serum potassium levels.
19 papers analyzed
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is commonly prescribed for hypertension and heart failure. However, its impact on potassium levels is a critical consideration, especially in patients with renal insufficiency or diabetes. Elevated potassium levels, or hyperkalemia, can pose significant health risks.
Research indicates that ACE inhibitors like lisinopril can significantly increase serum potassium levels in patients with renal insufficiency. A study comparing lisinopril and valsartan (an angiotensin receptor blocker) found that patients with a glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m² experienced a notable rise in serum potassium when treated with lisinopril. This increase was more pronounced compared to those treated with valsartan, suggesting that lisinopril has a stronger effect on potassium levels in this patient group.
Experimental studies on hypertensive Wistar rats have shown that lisinopril can elevate potassium levels. However, when lisinopril was administered alongside high-potassium foods like bananas, no significant drug-food interaction was observed, indicating that short-term combined intake does not exacerbate hyperkalemia risk in this model.
In a study comparing lisinopril and hydrochlorothiazide, lisinopril was found to increase serum potassium levels by 6%, whereas hydrochlorothiazide decreased potassium levels by 10%. This suggests that lisinopril has a potassium-sparing effect, which can be beneficial or detrimental depending on the patient's baseline potassium levels and renal function .
The ATLAS trial assessed the efficacy and safety of high-dose lisinopril in chronic heart failure patients, including those with diabetes. The study found that high-dose lisinopril was well-tolerated and effective in reducing mortality and hospitalization rates. Importantly, there were no consistent interactions between baseline potassium levels and treatment effects, indicating that high-dose lisinopril can be safely used in high-risk patients with careful monitoring.
Lisinopril has also been shown to improve insulin sensitivity in elderly hypertensive patients. This improvement was associated with a significant increase in fasting plasma potassium levels, suggesting a link between potassium balance and insulin action. The study highlighted that lisinopril administration led to better glucose disposal and reduced arterial blood pressure, further supporting its metabolic benefits.
Lisinopril, while effective in managing hypertension and heart failure, can significantly impact potassium levels, particularly in patients with renal insufficiency. Its potassium-sparing effect necessitates careful monitoring to prevent hyperkalemia. Comparative studies with other antihypertensive agents like valsartan and hydrochlorothiazide highlight the need for personalized treatment plans based on individual patient profiles. Overall, lisinopril remains a valuable therapeutic option with notable benefits for insulin sensitivity and cardiovascular outcomes, provided that electrolyte levels are closely monitored.
Most relevant research papers on this topic